TNF and inborn error of immunity: In this group, mortality varies greatly by type of immunosuppression, ranging from 3.2% in patients on TNF‐α blocker therapy [22] to 24.6% in solid organ transplant recipients [21] or 32% in a review that included mainly transplant recipients and patients with autoimmune conditions and primary immunodeficiency [23].